You are here

anemia

Incyte whittles down pipeline, scrapping 6 R&D programs

Incyte whittles down pipeline, scrapping 6 R&D programs

Fierce Biotech

Flag link:

FDA Accepts sBLA of BMS' Reblozyl

FDA Accepts sBLA of BMS' Reblozyl

Targeted Oncology

Bristol Myers Squibb

Flag link:

Genexine's anemia drug matches Roche-CSL product in phase 3, laying groundwork for Asia filings

Genexine's anemia drug matches Roche-CSL product in phase 3, laying groundwork for Asia filings

Fierce Biotech

chronic kidney disease

Flag link:

Docs likely to be 'cautious' when prescribing GSK's first-in-class anemia drug Jesduvroq, survey finds

Docs likely to be 'cautious' when prescribing GSK's first-in-class anemia drug Jesduvroq, survey finds

Fierce Pharma

Flag link:

GSK's oral anemia drug Jesduvroq scores partial FDA nod after 2 rivals suffered rejections

GSK's oral anemia drug Jesduvroq scores partial FDA nod after 2 rivals suffered rejections

Fierce Pharma

chronic kidney disease

Flag link:

AstraZeneca partner FibroGen slaps former employees with trade secret theft lawsuit

AstraZeneca partner FibroGen slaps former employees with trade secret theft lawsuit

Fierce Pharma

Flag link:

As GSK gears up for high-stakes daprodustat panel review, FDA flags some safety concerns

As GSK gears up for high-stakes daprodustat panel review, FDA flags some safety concerns

Fierce Pharma

Flag link:

Akebia Regains Rights to Anemia Drug After Otsuka Partnership Dissolves

Akebia Regains Rights to Anemia Drug After Otsuka Partnership Dissolves

BioSpace

Flag link:

As Sanofi prunes pipeline, ex-Alexion crew at Rallybio picks up anemia drug

As Sanofi prunes pipeline, ex-Alexion crew at Rallybio picks up anemia drug

Endpoints

Flag link:

GSK goes for gold as FDA starts review of daprodustat

GSK goes for gold as FDA starts review of daprodustat

Pharmaforum

chronic kidney disease

Flag link:

FDA rejects Akebia drug, dealing another blow to anemia pills

FDA rejects Akebia drug, dealing another blow to anemia pills

BioPharma Dive

Akebia Therapeutics

chronic kidney disease

Flag link:

Akebia scrapes together $85M war chest to commercialize vada as PDUFA date looms

Akebia scrapes together $85M war chest to commercialize vada as PDUFA date looms

Endpoints

Flag link:

Agios strategy shift pays off with FDA approval of first drug for rare anemia

Agios strategy shift pays off with FDA approval of first drug for rare anemia

MedCity News

Agios Pharmaceuticals

pyruvate kinase deficiency

Flag link:

Agios wins FDA approval for drug to treat rare form of anemia

Agios wins FDA approval for drug to treat rare form of anemia

Stat

pyruvate kinase deficiency

Flag link:

AstraZeneca, FibroGen hope to keep their roxadustat dream alive with new FDA meeting

AstraZeneca, FibroGen hope to keep their roxadustat dream alive with new FDA meeting

Fierce Pharma

Flag link:

GSK pulls off clean sweep of endpoint hits in anemia phase 3, positioning it to leapfrog AstraZeneca

GSK pulls off clean sweep of endpoint hits in anemia phase 3, positioning it to leapfrog AstraZeneca

Fierce Biotech

chronic kidney disease

cliincal trials

Flag link:

FibroGen, fresh off data manipulation scandal, touts win in cancer patients without revealing data

FibroGen, fresh off data manipulation scandal, touts win in cancer patients without revealing data

Endpoints

clinical trials

data manipulation

Flag link:

After FDA snub, EMA backs FibroGen, Astellas’ roxadustat

After FDA snub, EMA backs FibroGen, Astellas’ roxadustat

Pharmaforum

chronic kidney disease

Flag link:

FDA declines to approve FibroGen's anemia drug

FDA declines to approve FibroGen's anemia drug

Yahoo/Reuters

chronic kidney disease

Flag link:

Go or no go? Apellis and Heron head for the finish line

Go or no go? Apellis and Heron head for the finish line

EP Vantage

Heron Therapeutics

Flag link:

Pages